Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

BioChem Pharma Inc.

Hambrecht & Quist analyst Timothy Wilson reiterated his "buy" on BioChem Pharma

Read the full 141 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE